Concepedia

Author

Alfred Sandrock

Biogen (United States)

Also Known As

A Sandrock, A W Sandrock, A. Sandrock, A. W. Sandrock, A.W. Sandrock, Alfred Sandrock, Alfred W Sandrock, Alfred W. Sandrock

87

Publications

16.7K

Citations

35

H-Index

106

Concepts

All Affiliations

Biogen (United States)Harvard UniversityUniversity College LondonUniversity Hospital of BaselButler Hospital
AS

About

Alfred Sandrock is an author at Biogen (United States) specializing in medicine, neuroimmunology, and immunology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

19

21

6.5K

2

Health Sciences

5

5

294

3

Social Sciences

3

3

183

4

Arts

1

1

15

5

Allergy

1

1

43

Alfred Sandrock

×

43

Publications

15.5K

Citations

31

H-Index

YearCitations

A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis

Chris H. Polman, Paul O’Connor, Eva Havrdová,

New England Journal of Medicine

2006

3.3K

The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

Jeff Sevigny, Ping Chiao, Thierry Bussière,

Nature

2016

3K

Intramuscular Interferon Beta-1A Therapy Initiated during a First Demyelinating Event in Multiple Sclerosis

Lawrence Jacobs, Roy W. Beck, Jack H. Simon,

New England Journal of Medicine

2000

1.5K

Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis

Richard A. Rudick, William H. Stuart, Peter A. Calabresi,

New England Journal of Medicine

2006

1.3K

Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease

Samantha Budd Haeberlein, Paul Aisen, Frederik Barkhof,

The Journal of Prevention of Alzheimer s Disease

2022

1.2K

Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy

Gary Bloomgren, Sandra Richman, Christophe Hotermans,

New England Journal of Medicine

2012

1.2K

Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study

Darryl C. De Vivo, Enrico Bertini, Kathryn J. Swoboda,

Neuromuscular Disorders

2019

602

Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

Ludwig Kappos, Ralf Gold, David H. Miller,

The Lancet

2008

477

Anti‐JC virus antibodies: Implications for PML Risk Stratification

Leonid Gorelik, Michaela Lerner, Sarah A. Bixler,

Annals of Neurology

2010

430

MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS

David H. Miller, Derek Soon, Kryshani Fernando,

Neurology

2007

330

Page 1